Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Quadrature Capital Ltd

Quadrature Capital Ltd lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2,492.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,920 shares of the biopharmaceutical company’s stock after buying an additional 47,033 shares during the period. Quadrature Capital Ltd’s holdings in Alnylam Pharmaceuticals were worth $22,299,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ALNY. Arrowstreet Capital Limited Partnership boosted its position in shares of Alnylam Pharmaceuticals by 698.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock valued at $618,158,000 after acquiring an additional 1,185,909 shares during the last quarter. Employees Retirement System of Texas increased its position in Alnylam Pharmaceuticals by 3.4% during the third quarter. Employees Retirement System of Texas now owns 9,792 shares of the biopharmaceutical company’s stock worth $4,465,000 after purchasing an additional 318 shares during the last quarter. Mackenzie Financial Corp increased its position in Alnylam Pharmaceuticals by 7.7% during the third quarter. Mackenzie Financial Corp now owns 9,773 shares of the biopharmaceutical company’s stock worth $4,456,000 after purchasing an additional 698 shares during the last quarter. Quadrant Capital Group LLC purchased a new position in Alnylam Pharmaceuticals during the third quarter worth about $252,000. Finally, Capital Research Global Investors raised its stake in Alnylam Pharmaceuticals by 0.4% during the third quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company’s stock worth $3,293,516,000 after purchasing an additional 31,184 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Kevin Joseph Fitzgerald sold 2,290 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $370.33, for a total value of $848,055.70. Following the completion of the transaction, the executive vice president owned 21,264 shares in the company, valued at approximately $7,874,697.12. This trade represents a 9.72% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Pushkal Garg sold 2,242 shares of the company’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $695,199.36. Following the sale, the executive vice president owned 24,848 shares in the company, valued at $7,704,867.84. The trade was a 8.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 53,923 shares of company stock valued at $18,072,087. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Trading Down 1.0%

Shares of ALNY stock opened at $317.23 on Friday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The company has a 50 day moving average price of $346.09 and a 200 day moving average price of $410.94. The stock has a market capitalization of $42.07 billion, a P/E ratio of 185.51 and a beta of 0.36. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). The business had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.Alnylam Pharmaceuticals’s quarterly revenue was up 84.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.65) earnings per share. Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ALNY. Barclays began coverage on Alnylam Pharmaceuticals in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $527.00 price objective for the company. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, January 15th. Freedom Capital raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 17th. Leerink Partners dropped their price target on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research report on Monday, December 15th. Finally, Chardan Capital lowered their price objective on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating for the company in a research report on Friday, February 13th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $477.96.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.